

Amendment to the Specification:

Please replace page 10, paragraph 4, with the following paragraph:

--In a preferred embodiment of the present invention, the tryptase targeting construct is prepared directly from a plasmid genomic library using the methods described in U.S. Patent no. 6,815,185 issued November 9, 2004, which is based on U.S. Patent Application No. 09/885,816, filed June 19, 2001, which is a continuation of U.S. Application No. 09/193,834, filed November 17, 1998, now abandoned, which claims priority to provisional application no. 60/084,949, filed on May 11, 1998 and provisional application no. 60/184,194, and pending U.S. Patent Application Ser. No.: 08/971,310, filed November 17, 1997, which was converted to provisional application no. 60/084,949, filed on May 11, 1998, the disclosure of provisional application no. 60/084,194 the disclosure of which is incorporated herein in its entirety. Generally, a sequence of interest is identified and isolated from a plasmid library in a single step using, for example, long-range PCR. Following isolation of this sequence, a second polynucleotide that will disrupt the tryptase sequence can be readily inserted between two regions encoding the sequence of interest. In accordance with this aspect, the construct is generated in two steps by (1) amplifying (for example, using long-range PCR) sequences homologous to the tryptase sequence, and (2) inserting another polynucleotide (for example a selectable marker) into the PCR product so that it is flanked by the homologous sequences. Typically, the vector is a plasmid from a plasmid genomic library. The completed construct is also typically a circular plasmid.--

Please replace page 11, paragraph 1 with the following:

--In another embodiment, the tryptase targeting construct is designed in accordance with the regulated positive selection method described in U.S. Patent Application Ser. No. 60/232,957, filed September 15, 2000, the disclosure of which is incorporated herein in its entirety, upon which U.S. Patent Application Ser. No. 09/954,483, filed September 17, 2001 is based, which is now published

U.S. Patent Publication No. 20030032175. The tryptase targeting construct is designed to include a PGK-*neo* fusion gene having two *lacO* sites, positioned in the PGK promoter and an NLS-*lacI* gene comprising a lac repressor fused to sequences encoding the NLS from the SV40 T antigen.--